Real‐world treatment burden of brentuximab vedotin‐based front‐line regimens in young adults and adults with advanced‐stage classical Hodgkin lymphoma
Year: 2026
Type: article
Abstract: Real-world treatment burden of brentuximab vedotin-based frontline regimens in young adults and adults with advanced-stage classical Hodgkin lymphomaTo the Editor, We read with great enthusiasm the multicentre, retrospective study by Porges et al. in British Journal of Haematology in August 2026, 1 assessing front-line brentuximab vedotin, etoposide, cyclophosphamide, doxorubicin, dacarbazine, dexamethasone (BrECADD) in 100 advanced-stage classical Hodgkin lymphoma (cHL) patients (median age, 30 years).The outstanding disease control reported by the
Source: British Journal of Haematology
DOI: 10.1111/bjh.70951
Authors: Annamaria Vincenzi(Methodology, Validation, Visualization, Writing – original draft, Writing – review & editing), Marco Picardi(Conceptualization, Project administration, Supervision, Writing – original draft, Writing – review & editing), Claudia Giordano(Investigation, Methodology, Validation, Visualization, Writing – review & editing), Novella Pugliese(Investigation, Methodology, Validation, Visualization, Writing – review & editing), Sara Pellegrino(Data curation, Investigation, Methodology, Validation, Visualization, Writing – review & editing), Fabrizio Pane(Writing – review & editing)
Language: English
Subfield: Pathology and Forensic Medicine
Field: Medicine
Domain: Health Sciences
Open Access status: hybrid
Estimated APC paid: $5,190
OpenAlex ID: W7236701555
